

1 **Title page**

2 Main title: Evaluating the Safety Profile of the CoronaVac in Adult and Elderly populations: A Phase IV
3 Prospective Observational Study in Brazil

4 Short-title: Safety profile of CoronaVac in Brazil

5 Authors and affiliations: Monica Akissue de Camargo Teixeira Cintra¹, Eder Gatti Fernandes¹, Vanessa Infante¹,
6 Ana Paula Loch¹, Lucas Ragiotto¹, Patrícia Emília Braga¹, Maria da Graça Salomão¹, Maria Beatriz Bastos
7 Lucchesi¹, Mayra Martho Moura de Oliveira¹, Vera Lúcia Gattás¹, Anderson Soares da Silva², Paulo José Fortes
8 Villas Boas³, Marta Heloisa Lopes⁴, José Moreira^{1*}, Fernanda Castro Boulos¹, CFV-01-IB study group[#]

9 ¹Clinical Trials and Pharmacovigilance Center, Instituto Butantan, São Paulo, Brazil.

10 ² Centro de Saúde Escola da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (HCFMRP-
11 USP) Dr. Joel Domingos Machado.

12 ³ Centro de Saúde Escola da Faculdade de Medicina de Botucatu – Unesp.

13 ⁴ Centro de Referência de Imunobiológicos Especiais Hospital das Clínicas da Faculdade de Medicina da
14 Universidade de São Paulo (CRIE-HCFMUSP).

15 [#]Members of the CFV-01-IB study group are listed in the Supplementary Appendix

16 Corresponding author: José Moreira, MD, PhD, Clinical Developmental Medical Director, Center of Clinical
17 Trials and Pharmacovigilance, Instituto Butantan. Av. Vital Brasil 1500. São Paulo, Brazil, 05503-900. Phone:
18 +55(21) 97035-8843.

19 E-mail: jose.amoreira @butantan.gov.br

20 Keywords: CoronaVac; Adverse Events Following Immunization; Covid-19 vaccine; Adult vaccination; Active
21 Pharmacovigilance, Phase IV trial, Covid-19

22

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 **Abstract**

24 Objective: This Phase IV prospective observational study aimed to evaluate the safety and
25 monitor adverse events following immunization (AEFI) associated with CoronaVac, an
26 inactivated SARS-CoV-2 vaccine, in Brazilian adult (18-59 years) and elderly (≥ 60 years)
27 populations.

28 Methods: Participants (n=538; 487 adults and 51 elderly) were enrolled from three public
29 health services in São Paulo, Brazil. A two-dose vaccination regimen, administered 14 days
30 apart, was used. The study assessed Adverse Reactions (AR) necessitating medical attention
31 within seven days post-vaccination dose and monitored AEFI for a period of 42 days. Safety
32 was monitored through a review of participant diary cards, telephone contacts, and on-site
33 study visits.

34 Results: Among adults, the most frequently reported local AR after the first and second dose
35 was pain (256[52.6%] and 129 [29.5], respectively), while the most common systemic reaction
36 was a headache (158[34.5%] and 51 [11.6%], respectively). Most local and systemic solicited
37 ARs were of Grade 1 or 2, with these reactions being more prevalent in adults after the first
38 dose. One serious adverse event possibly related to the vaccine was reported among adults, but
39 there were no fatalities. Nine adult participants experienced adverse events of special interest,
40 which included five cases of Covid-19.

41 Conclusion: CoronaVac demonstrated safety and tolerability in the observed population.
42 Ongoing post-marketing surveillance is crucial for the identification of rare adverse events and
43 further affirmation of the vaccine's safety profile.

44 **ClinicalTrials.gov Identifier:** NCT04845048

45

46 **Introduction**

47 The swift development of SARS-CoV-2 vaccines and their subsequent rapid market
48 authorization process in response to the Covid-19 pandemic has underscore the importance of
49 pharmacovigilance. This practice manages the substantial number of reported suspected
50 adverse events following immunization (AEFI) and its implications for the global vaccination
51 campaign [1].

52 Instituto Butantan (IB), a Brazilian public biomedical research and manufacturing institution,
53 has played a pivotal role in Covid-19 governance in Brazil. In 2020, IB initiated a phase 3
54 clinical trial to evaluate efficacy and safety of CoronaVac in first-line healthcare professionals
55 in Brazil [2]. In January 17th, CoronaVac was granted Emergency Use Authorization (EUA)
56 by the National Health Surveillance Agency (ANVISA).

57 However, the large participants samples in a phase 3 trial have limitations in detecting rare
58 adverse events. Routine pharmacovigilance activities typically depend on spontaneous
59 reporting, which highlights the crucial role of post-marketing safety surveillance in prioritizing
60 vaccine rollout and equitable access. Following ANVISA recommendations, IB undertook a
61 post-market approval safety evaluation to characterize AEFI associated with CoronaVac in
62 adults and the elderly during the vaccination campaign in Brazil.

63 **Methods**

64 Study design and setting

65 This phase IV prospective observational study monitored the safety of CoronaVac after a
66 minimum of 1-dose administration. The study, registered on clinicaltrials.org prior to data
67 acquisition (NCT04845048), was conducted from May 2021 to January 2022 across three
68 public health services, in São Paulo state, Brazil. The study commenced after ANVISA issued

69 an EUA for CoronaVac on January 17th, 2021. Ethical approval was obtained from the
70 coordinating study site (University of São Paulo, protocol number: 4.684.670) and the
71 collaborating study sites - Centro de Referência de Imunobiológicos Especiais/Hospital das
72 Clínicas da Faculdade de Medicina da Universidade de São Paulo (CRIE-HCFMUSP), Centro
73 de Saúde Escola da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
74 (HCFMRP-USP), and Centro de Saúde Escola da Faculdade de Medicina de Botucatu – Unesp.
75 Written informed consent was obtained from all study participants according to local IRBs. We
76 reported as per the Strengthening the Reporting of Observational Studies in Epidemiology
77 (STROBE) guideline (refer to Supplementary appendix).

78 Participants

79 Eligible participants for the CoronaVac vaccine, aged 18-59 years-old (adults) and ≥ 60 years
80 (elderly), were recruited based on the criteria of the national immunization program in Brazil
81 during the study [3]. Potential participants were invited to join the study, with participation
82 contingent on signing an informed consent form and agreement to adhere to study procedures.
83 Individuals with a history of allergic reactions or anaphylaxis to previous immunizations,
84 allergy to any CoronaVac component, fever (axillary temperature $\geq 37.8^{\circ}$ C) within 72 hours
85 prior to vaccination, or unavailable throughout the study period (42 days or 60 days in case of
86 women with childbearing potential) were considered ineligible .

87 Primary and secondary endpoints

88 The primary safety endpoint entailed the characterization of adverse reactions requiring
89 medical care and assistance within 7 days post-administration of any of the two CoronaVac
90 doses (14 days apart). The secondary endpoints encompassed: 1) characterization of AEFI
91 requiring medical attention within 42 days post-administration of any dose, considering
92 incidence, causality, and seriousness; 2) characterization of adverse reactions within 30

93 minutes post-administration of any dose, considering incidence and seriousness, 3)
94 characterization of serious adverse event (SAE) within a 42-day period post-administration of
95 any dose of the vaccine, stratified by age group, and 4) profiling of adverse event of special
96 interest (AESI) within a 42-day period post-administration of any dose of the vaccine, stratified
97 by age group. Adverse events were categorized on dose incidence, causality, severity, and age
98 group. The exploratory endpoints included documenting adverse events among pregnant
99 women and their exposed infants.

100 Study procedures for active surveillance

101 The study entailed two visits to the clinical centers (V1 -initial screening and first dose
102 vaccination; V2 - second dose vaccination and surveillance assessment through participant
103 diary card review, and seven telephone contacts (C1 to C7 - for active AE surveillance). If
104 eligible, participants received the first vaccine dose and remaining under observation at the
105 clinical center for 30 minutes for immediate hypersensitivity AEFI assessment and solicited
106 AEFI recording (V1 and V2). Clinical center staff also gathered information concerning
107 demographics (sex, age, and race), medical history, concomitant medication, ongoing
108 pregnancies and infants (where applicable), vaccination site (right arm/left arm/other),
109 administration route (intramuscular/other) and volume (0.5mL/other), vaccine batch,
110 manufacturing date and expiration date.

111 After vaccination, each participant was evaluated by study site staff for immediate occurrence
112 of solicited and unsolicited AEFI. Before departing, participants received a diary card for
113 solicited and unsolicited adverse events up to 7 days post-vaccination, a device for measuring
114 local site AEFI, a thermometer, and instructions for use. Participants were further instructed to
115 return to the study site for a second visit (V1 + 14 days tolerance), respond to scheduled
116 telephone calls [C1 (V1 + 3-5 days) and C2 (V1 + 7-9 days)], and promptly notify study staff

117 in the event of hospitalization and/or SAE. Participants were also provided instructions on how
118 to record AEFIs and assess the severity/intensity of the AEFIs using a simple scoring system.
119 AEFIs occurring during pregnancy or related to newborns were documented, if applicable.
120 Information regarding AEFIs recorded in participant diary card and solicited AEFIs were
121 collected by the sites during subsequent telephone contacts [C3 (V2 + 3-5 days), C4 (V2 + 7-
122 9 days), C5 (V2 + 14-16 days), C6 (V2 + 42-45 days) and C7 – end of study (V2 + 60-63
123 days)]. During the second visit (V1 + 14 - 31 days), participants underwent physical
124 examination and concomitant medication review. Possible pregnancy information was
125 gathered, if applicable. Data recorded in the participant dairy cards were scrutinized by site
126 center medical staff.

127 Safety assessment

128 In this context, an adverse event was defined as any undesirable medical occurrence that
129 affected a vaccinated participant, regardless of its causal relationship to the vaccine.
130 Consequently, an adverse event could comprise any unfavorable and unintended sign,
131 symptom, or disease (including an abnormal laboratory findings), temporally associated with
132 the vaccination. All adverse events were encoded and categorized in accordance with the
133 Medical Dictionary for Regulatory Activities (MedDRA, version 24.0) [3]. A Serious Adverse
134 Event (SAE) was characterized as any adverse event resulting in outcomes such as death, a
135 life-threatening condition, the necessity for hospitalization or an extension of an existing
136 hospitalization, significant or persistent incapacitation, congenital anomaly, any suspected
137 transmission of an infectious agent through a medicinal product, or any clinically significant
138 adverse event. An Adverse Reaction (AR) was defined as any AE with a plausible causal
139 relationship with the vaccine, as determined by the adapted classification of the Uppsala
140 Monitoring Centre (UMC) of the World Health Organization (WHO) [4][5]. An adverse event

141 of special interest was a predefined, medically significant event that might potentially be
142 causally associated with a vaccine product, warranting close monitoring and confirmation via
143 additional specific studies [6].

144 The severity of an AE was classified from grade one to four according to the Toxicity Grading
145 Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical
146 Trials of the US Food and Drug Administration (FDA) [7]. The study staff was instructed to
147 incorporate the following information in their AE evaluations: the classification of seriousness;
148 the classification of severity [4], causality assessment, and adverse event outcome
149 (Supplementary information).

150 The definitions and classifications of adverse events were in accordance with the
151 recommendations stipulated by the Good Clinical Practices (GCP) [8], the Guideline on
152 Clinical Safety Data Management from the International Conference on Harmonization (ICH)
153 [5], and the Brighton Collaboration's guidance on safety data collection for COVID-19 vaccine
154 safety [6]. In instances where case definitions were not provided by Brighton Collaboration
155 sources, the Common Terminology Criteria for Adverse Events (CTCAE) issued by the US
156 Department of Health and Human Services [9] were utilized as reference.

157 *Study vaccine*

158 The study vaccine is an inactivated whole-virion vaccine with aluminum hydroxide serving as
159 the adjuvant, prepared with a novel coronavirus strain (CZ02 strain) inoculated in African green
160 monkey kidney cells (Vero cells) [10]. The inactivation process involved adding β -
161 propiolactone to the virus harvest fluid at a ratio of 1:4000 and inactivating at 2-8° C for 12-24
162 h. A single dose of the vaccine contains 3 μ g of SARS-CoV-2 virion in a 0.5 mL aqueous
163 suspension for injection with 0.45 mg/mL of aluminum. The vaccine was administered in two
164 doses, delivered 14 days apart, intramuscularly in the deltoid muscle. The vaccine is free of

165 preservatives and the final packaging includes a single-dose vial with an extractable volume of
166 0.5 mL, a vial with two doses of 0.5 mL each, or a multi-dose vial containing 5 mL, with each
167 vaccine dose corresponding to 0.5 mL.

168 Sample size estimation

169 The sample size was estimated following the recommendation of the Guide to Clinical
170 Evaluations of New Vaccines (EMA/CHMP/VWP/164653/2005) [11], suggesting that at
171 least 100 participants from each vaccination target group should have AEFI monitored. Thus,
172 a sample of 900 vaccinated participants (600 adults and 300 elderly) was estimated for the
173 evaluation of solicited and unsolicited AEFI through active surveillance.

174 This sample size was based on the formula presented below, assuming the observation of an
175 AE at an established minimum frequency equal to M (maximum risk). $N = \ln(\alpha) / \ln(1-M)$ Type
176 I error parameter (α) adopted was 5% (two-tailed) and N for elderly=300, to achieve AE
177 frequency detection of approximately 1% (maximum risk of 1 to 100), whereas N for adults=
178 600 achieves AE frequency at a maximum risk of 1 in 200.

179 Statistical analysis

180 Descriptive statistical data analysis of AE and AR was performed, stratified by study groups
181 (younger and older adults) and dose vaccination [12]. Results are presented as the frequency
182 of occurrence (absolute and percentage values) for qualitative variables and as dispersion
183 measures (quartiles) for quantitative variables. Missing data were handled with the list-wise
184 deletion method. The statistical analyses were conducted using Stata (Stata-Corp LP, College
185 Station, Texas USA), version 13.0, for Windows.

186 **Results**

187 Participants

188 Figure 1 presents the study participants' flowchart, segmented to age groups. The study
189 incorporated a total of 538 participants, where young adults represented 90.5% (487/538) of
190 the sample and older adults constituted 9.5% (51/538). Table 1 provides a description of the
191 participants' baseline socio-demographic characteristics. The median age for young adults was
192 30.5 years, and for the oldest adults, its was 65.3 years. The majority of participants were
193 female (57.1%) and identified as white (59.3%).

194 The median occurrence of AE and AR per participant was three following the first dose, and
195 varied from one to three following the second-dose., across the entire population (Table 2).
196 Both AE and AR were more frequent in the 18-59-year-old group after the first dose (V1).
197 Only one SAE was reported as possibly related to vaccination, with no registered cases of death
198 or permanent impairment. The AE and AR were more frequent after V1 in the 18–59-year-old
199 group.

200 Primary endpoint

201 For adults, considering the primary endpoints, 76.0% experienced solicited AR after the first
202 dose, and 42.5% after the second dose, within a 7-day post-vaccination period (Table 3). The
203 most common local AR after both doses was pain at the administration site (256 [52.6%] and
204 129 [29.5%], respectively). The majority of local and systemic solicited AR were classified as
205 Grade 1 or Grade 2 (Table S1). Thirty-five cases (3.0%) were classified as Grade 3 after the
206 first dose, while 10 cases (2.6%) after the second. Only three ARs were classified as Grade 4
207 (1 headache, 1 fatigue and 1 myalgia), all following the first dose.

208 For the elderly, considering the primary endpoints, 43.1% experienced solicited AR after the
209 first dose, and 44.0 % after the second dose, within a 7-day post-vaccination period (Table 4).

210 The most common local AR was pain at the administration-site (9 [17.7%] and 11 [22.0%]
211 after first and second dose, respectively) and the most frequent systemic AR one was headache
212 (9 [17.7%] and 10 [20.0%] after first and second dose, respectively). The majority of local and
213 systemic solicited AR were classified as Grade 1 or Grade 2 (Table S2). Only one episode of
214 myalgia was classified as Grade 3, no local and systemic solicited AR were classified as Grade
215 4.

216 Frequency and severity of solicited and unsolicited AR within 7-days post-vaccination for
217 adults and elderly are available in the Supplementary material (Table S1 and Table S2).

218 Secondary endpoint

219 Table 5 displays the frequency of adults and elderly experiencing solicited AR 30 minutes post
220 each vaccination. The solicited AR were more common after the first dose among adults (129
221 [26.5%] vs 84 [19.2%]). Data suggests that solicited AR were less frequent among the elderly,
222 with no noticeable difference between the first and the second dose (6 [11.8%] and 6 [12.0%],
223 respectively). The frequency and intensity of unsolicited AR 30 minutes post-vaccination in
224 adults and elderly can be found in the Supplementary material (Table S3).

225 The frequency of AR that required medical intervention and the SAE 42-days post vaccination
226 are outlined in Table S4. There were no SAE reports in the elderly group. Only one SAE
227 (migratory polyarthralgia) was assessed by the Investigator and considered possibly related to
228 the vaccine. All participants that presented any AR that required medical intervention or SAE
229 had fully recovered.

230 Nine adult participants experienced AESI. These included five cases of Covid-19, two cases of
231 arthritis, one case of tachycardia, and one case of acute renal failure. The frequency, causality
232 assessment and intensity of the AESI can be found at Supplementary material (Table S5).

233 Exploratory endpoints

234 Among pregnant participants (n=2), seven non-serious AR were reported. All these cases
235 recovered. Detailed information about the AE in pregnant women and infants can be found in
236 Supplementary material (Table S6).

237 **DISCUSSION**

238 The expedited development and EUA of Covid-19 vaccines have been instrumental in
239 mitigating the global impact of the SARS-CoV-2 pandemic, especially during its acute phase
240 [13]. Among these vaccines, CoronaVac, developed by Sinovac Biotech and later transferred
241 to IB, has been extensively utilized in numerous countries. However, upon EUA, safety data
242 for CoronaVac, as with all Covid-19 vaccines authorized during this public health crisis, were
243 limited, thus necessitating rigorous post-vaccination real-world safety data.

244 The ANVISA recognizing this knowledge gap commissioned a comprehensive post-
245 authorization safety study on CoronaVac in adults and elderly populations. The aim was to
246 document its safety profile, particularly focusing on the identification and characterization of
247 AEFI among adults and the elderly populations. The real-world nature of this study offered the
248 opportunity to evaluate the vaccine's safety profile in a broader and more diverse population
249 than those included in clinical trials. Our findings suggest that most AE and AR following
250 vaccination were mild to moderate in severity and resolved spontaneously. The frequency of
251 AR, solicited and unsolicited, was greater in younger adults than in elderly, especially after the
252 first dose. Only one SAE was reported, suggesting a satisfactory safety profile of the vaccine.

253 Brazilian national passive surveillance data reported a 6.6% rate of SAE following CoronaVac
254 [14], whereas our study identified a significantly lower rate of 0.6%. Unlike passive
255 pharmacovigilance, which relies on voluntary spontaneous reporting of AE, active

256 pharmacovigilance facilitates the procurement of more detailed safety information. The passive
257 surveillance is more sensitive to SAE, but the data quality is weak [15][16]. A strength of our
258 research is the active surveillance of AEFI by follow-up phone calls after each dose. This
259 procedure made possible to capture more detailed mild and moderate events, which are
260 typically underreported in passive surveillance systems [15]. Another strength of this study is
261 the low dropout rate, which reinforces the good tolerability of the vaccine. Additionally, the
262 participants presented different risk levels of exposure to Covid-19.

263 Our study has limitations. Sample size did not reach the previously calculated number of
264 participants because the public vaccination campaign started 3 months earlier than the protocol
265 approval, including other vaccines rather than CoronaVac. Due to this difficulty to include
266 unvaccinated subjects, and therefore, the reduction in sample size, the minimum of AE
267 detection power for adults was $M=1/165 \approx 0.6\%$ whereas for elderly was $M=1/18 \approx 5.7\%$. The
268 demographic distribution of the sample population, which had a considerably larger
269 representation of younger adults than older ones might potentially introduce some bias in the
270 results and explain the observed higher vaccine reactogenicity in the younger adults compared
271 to older ones. After CoronaVac's EUA extension to the pediatric population in January 20th,
272 2022, a protocol amendment was made to include children and adolescents, enabling safety
273 information collection for this group. Albeit the above sample size limitations, our data are
274 consistent with other studies that suggest CoronaVac are well tolerated with a relatively lower
275 frequency of AE regardless of age [10] [17] [18] .

276 Our findings showed that the majority of ARs were mild to moderate [Grade 0 and Grade 1:
277 (962/1157 - 83.1%)], which coincides with previous reports evaluating this vaccine [10] [17]
278 [18]. Most AE were low grade and resolved spontaneously, supporting the findings reported
279 by Tanriover et al. [10] and Wu et al. [19] in Turkey and China, respectively. Most of the

280 solicited AR reported by the participants lasted less than a day, differently from data in Xia et
281 al. [20] as well as Zhang et al. [21] studies which reported adverse reactions lasting for up to
282 72h after the complete schedule of vaccine administration in healthy adults. Most common
283 adverse events reported in our study, such as local pain, headache, and myalgia, were also
284 observed in other studies evaluating CoronaVac and are listed in the vaccine package insert.
285 Regarding the most frequent local and systemic adverse reactions by inactivated virus Covid-
286 19 vaccine, Ling et al. [22] reported pain, swelling, and fever at the injection site, whereas Chen
287 et al. [23] reported pain, swelling and redness at the injection site. Systemic AEFI such as
288 headache (34.5%) and fatigue (21.97%) predominated in our study. Results from randomized
289 trials in Indonesia have listed headache and malaise as the most significant systemic AEFI [24].
290 Indonesian results pointed out gender related AEFI after CoronaVac immunization in which
291 females presented higher frequency of AEFI than male participants.

292 Our study adds to the growing body of evidence on the safety of SARS-CoV-2 vaccines,
293 particularly CoronaVac. It equips clinicians with pertinent information for patient counseling
294 about potential CoronaVac side effects and provides policymakers with crucial data to inform
295 vaccination strategies and campaigns. In fact, our data helped consolidate the safety profile of
296 CoronaVac in the Brazilian's Covid-19 vaccine response plan.

297 In conclusion, our data substantiate the overall safety of the CoronaVac in adults and elderly
298 individuals, with side effects being generally mild and transient. However, continuous
299 monitoring for rare AE remains crucial. These findings should bolster confidence in
300 CoronaVac among clinicians, policymakers, and the public, while encouraging further research
301 on Covid-19 vaccines in various demographic and epidemiological settings.

302 **Acknowledgments**

303 We thank the study volunteers. The study's conception, design, conduct, analysis, and
304 interpretation, as well as the drafting and submission of this manuscript, involved the IB staff.
305 The corresponding author had full access to the study data and had final responsibility for the
306 decision to submit for publication.

307 **Declarations**

308 **Funding:** This study was sponsored by Fundação Butantan (FB).

309 **Consent to participate:** All participants gave informed consent to participate in this study,
310 where publication was identified as one form of dissemination. Information and Study Consent
311 Forms available upon request.

312 **Ethics approval:** Approval for this research was granted by the Ethical Committee of the
313 University of São Paulo (protocol number: 4.684.670).

314 **Conflict of interest:** JM is Associate Editor for PLoS One. MC, VI, AL, LR, PB, MS, ML, MO,
315 VG, JM, and FB are current employees of Instituto Butantan. EF is a former employee of
316 Instituto Butantan. ASS, MHL and PJFVB were principal investigators.

317 **Data availability:** All data are available in the text and in the supplementary appendix for
318 consultation.

319

320

321

322 References

- 323 1. Rudolph A, Mitchell J, Barrett J, Sköld H, Taavola H, Erlanson N, Melgarejo-González
324 C, Yue QY. Global safety monitoring of COVID-19 vaccines: how pharmacovigilance
325 rose to the challenge. *Ther Adv Drug Saf.* 2022 Aug 25; 13:20420986221118972. doi:
326 10.1177/20420986221118972.
- 327 2. Palacios R, Patino EG, Piorelli RdO, et al. Double-blind, randomized, placebo-
328 controlled phase III clinical trial to evaluate the efficacy and safety of treating
329 healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine
330 manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for
331 a randomized controlled trial. *Trials.* 2020; 21(1): 853.
- 332 3. MedRA dictionary International Conference on Harmonization. The medical dictionary
333 for regulatory activities. <https://www.meddra.org/> .
- 334 4. WHO/UMC/ The use of the WHO-UMC system for standardised case causality
335 assessment [Internet]. Uppsala: The Uppsala Monitoring Centre. [http://www.who-](http://www.who-umc.org/Graphics/24734.pdf)
336 [umc.org/Graphics/24734.pdf](http://www.who-umc.org/Graphics/24734.pdf) .
- 337 5. ICH Clinical Safety Data management: Definitions and Standards for Expedited
338 Reporting [Internet]. Geneva: International Conference on Harmonisation of
339 Technical Requirements or Registration of Pharmaceuticals for Human Use; 2003.
340 E2A. Accessed on 12 February 2019.
341 [https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E](https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf)
342 [2D/Step4/E2D_Guideline.pdf](https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2D/Step4/E2D_Guideline.pdf) .
- 343 6. World Health Organization (WHO) Global manual on surveillance of adverse events
344 following immunization 2014/2016,
345 <https://apps.who.int/iris/rest/bitstreams/914830/retrieve>. Accessed on 12 December
346 2021.

- 347 7. CBER/USFDA/USDHHS Guidance for Industry: Toxicity Grading Scale for Healthy
348 Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials
349 [Internet]. Silver Spring: US Food and Drug Administration; 2007 [cited 2011 Set 29].
350 [http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegula](http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf)
351 [toryInformation/Guidances/Vaccines/ucm091977.pdf](http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091977.pdf).
- 352 8. European Medicines Agency. Integrated addendum to ICH E6Rr1: guideline for good
353 clinical practice E6(R2). London: EMA; 2016. [cited 2018 Jul 2].
354 [https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E](https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2_Step_4_2016_1109.pdf)
355 [6/E6_R2_Step_4_2016_1109.pdf](https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R2_Step_4_2016_1109.pdf).
- 356 9. NIC/NIH NCI Common Terminology Criteria for Adverse Events (CTCAE) [Internet].
357 <http://evs.nci.nih.gov/ftp1/CTCAE/About.html>.
- 358 10. Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated
359 whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind,
360 randomised, placebo-controlled, phase 3 trial in Turkey; *Lancet*. 2021;
361 398(10296):213-222.
- 362 11. Rego GNA, Nucci MP, Alves AH, Oliveira LCM, Nucci LP, Mamani JB, Gamarra LF.
363 Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-
364 CoV-2. *Review Vaccines*. 2020; 8, 474.
- 365 12. Ministério da Saúde, Brasil. 2021. Manual De Vigilância Epidemiológica De Eventos
366 Adversos Pós-Vacinação. 4th edition. [https://www.gov.br/saude/pt-br/centrais-de-](https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/publicacoes-svs/vacinacao-imunizacao-pni/manual_eventos-adversos_pos_vacinacao_4ed_atualizada.pdf)
367 [conteudo/publicacoes/publicacoes-svs/vacinacao-imunizacao-pni/manual_eventos-](https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/publicacoes-svs/vacinacao-imunizacao-pni/manual_eventos-adversos_pos_vacinacao_4ed_atualizada.pdf)
368 [_adversos_pos_vacinacao_4ed_atualizada.pdf](https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/publicacoes-svs/vacinacao-imunizacao-pni/manual_eventos-adversos_pos_vacinacao_4ed_atualizada.pdf)/ accessed on 20 October, 2022.
- 369 13. Grana C, Ghosn L, Evrenoglou T, et al. Efficacy and safety of COVID-19 vaccines.
370 *Cohrane Database Syst Rev*. 2022; 12(12):CD015477.
- 371 14. Ministério da Saúde, Brasil. 2021. Manual De Vigilância Epidemiológica De Eventos
372 Adversos Pós-Vacinação. 4th edition. [https://www.gov.br/saude/pt-br/centrais-de-](https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/publicacoes-svs/vacinacao-imunizacao-pni/manual_eventos-adversos_pos_vacinacao_4ed_atualizada.pdf)

- 373 [conteudo/publicacoes/publicacoes-svs/vacinacao-imunizacao-pni/manual_eventos-](#)
374 [adversos_pos_vacinacao_4ed_atualizada.pdf/](#) accessed on 20 October, 2022.
- 375 15. Rosenthal S, Chen R. The reporting sensitivities of two passive surveillance systems
376 for vaccine adverse events. *Am J Public Health*. 1995 Dec;85(12):1706-9. doi:
377 10.2105/ajph.85.12.1706.
- 378 16. CIOMS 2017. CIOMS guide to active vaccine safety surveillance. [https://cioms.ch/wp-](https://cioms.ch/wp-content/uploads/2020/04/240WEB-CIOMS-Guide-AVSS-20170202-protected.pdf)
379 [content/uploads/2020/04/240WEB-CIOMS-Guide-AVSS-20170202-protected.pdf](https://cioms.ch/wp-content/uploads/2020/04/240WEB-CIOMS-Guide-AVSS-20170202-protected.pdf).
- 380 17. Miyaji KT, Itto LYU, Jacintho LC et al. Adverse events following immunization of
381 elderly with COVID-19 inactivated virus vaccine (CoronaVac) in Southeastern Brazil:
382 an active surveillance study. *Rev Inst Med Trop Sao Paulo*. 2022; 64: e56.
- 383 18. Makadzange AT, Gundidza P, Lau C, et al. Vaccine adverse events following COVID-
384 19 vaccination with inactivated vaccines in Zimbabwe. *Vaccines (Basel)*. 2022; 10(100):
385 1767.
- 386 19. Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, et al. Safety, tolerability, and
387 immunogenicity of an inactivated SARSCoV-2 vaccine (Coronavac) in healthy adults
388 aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2
389 clinical trial. *Lancet Infect Dis*. 2021;21:803-12.
- 390 20. Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W,
391 Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L,
392 Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S,
393 Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Effect of an Inactivated Vaccine
394 Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2
395 Randomized Clinical Trials. *JAMA*. 2020 Sep 8;324(10):951-960. doi:
396 10.1001/jama.2020.15543.
- 397 21. Zhang YJ, Zeng G, Pan HX, Li CG, Kan B, Hu YL, Mao HY, Xin QQ, Chu K, Han WX,
398 Chen Z, Tang R, Yin WD, Chen X, Gong XJ, Qin C, Hu YS, Liu XY, Cui GL, Zhu FC
399 (2020b) Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy

400 adults aged 18–59 years: report of the randomized, doubleblind, and placebo-
401 controlled phase 2 clinical trial. *medRxiv* 2020b (p. 2020.07.31.20161216). Doi:
402 <https://doi.org/10.1101/2020.07.31.20161216>.

403 22. Ling Y, Zhong J, Luo J. Safety and effectiveness of SARS-CoV-2 vaccines: A
404 systematic review and meta-analysis. *J Med Virol*. 2021 Dec;93(12):6486-6495. doi:
405 10.1002/jmv.27203. Epub 2021 Jul 26.

406 23. Chen M, Yuan Y, Zhou Y, Deng Z, Zhao J, Feng F, Zou H, Sun C. Safety of SARS-
407 CoV-2 vaccines: a systematic review and meta-analysis of randomized controlled
408 trials. *Infect Dis Poverty*. 2021 Jul 5;10(1):94. doi: 10.1186/s40249-021-00878-5.

409 24. Supangat, Sakinah EN, Nugraha MY, Qodar TS, Mulyono BW, Tohari AI. COVID-19
410 Vaccines Programs: adverse events following immunization (AEFI) among medical
411 Clerkship Student in Jember, Indonesia. *BMC Pharmacol Toxicol*. 2021 Oct
412 12;22(1):58. doi: 10.1186/s40360-021-00528-4.

413 .

414

415

416

417

418

419

420

421

422 **Tables and Figure:**

423 Figure 1. Study flowchart: screening, enrollment, and vaccination.

424 Table 1. Demographic characteristics of all participants by study group.

425 Table 2. Frequency of Adverse Events and Adverse Reactions after CoronaVac vaccination
426 (first and second dose) by study group.

427 Table 3. Frequency of solicited adverse reactions (AR) 7 days post vaccination in adults (18 -
428 59 years).

429 Table 4. Frequency of solicited adverse reactions (AR) 7 days post vaccination in elderly (≥ 60
430 years).

431 Table 5. Frequency of Adverse reactions (AR) 30 minutes post vaccination in adults (18 - 59
432 years) and elderly (≥ 60 years).

433 **Supporting information captions**

434 S1 Table. Frequency and severity of adverse reactions, solicited (local and systemic) and
435 unsolicited, occurring up to 7 days after administration of each vaccine dose in adults (18 to
436 59 years), according to severity


437 S2 Table. Frequency and severity of adverse reactions, solicited (local and systemic) and
438 unsolicited, occurring up to 7 days after administration of each vaccine dose in elderly (≥ 60
439 years), according to severity

440 S3 Table. Frequency of adverse reactions, solicited (local and systemic) and unsolicited,
441 occurring within 30 minutes after administration of each vaccine dose in a) adults (18-59
442 yeas) and b) elderly (≥ 60 years), according to severity

443 S4 Table. Frequency of solicited (local and systemic) and unsolicited adverse reactions
444 which required medical attention, occurring at any time within 42 days after administration of
445 each vaccine dose in a) adults (18-59 years) and b) elderly (≥ 60 years), according to
446 severity

447 S5 Table. Serious adverse events and adverse events of special interest according to the
448 administration dose regarding description (MedRA code), causality, severity, predictability
449 and outcomes

450 S6 Table. Adverse event details observed in pregnant women and newborn according to the
451 administration dose regarding description code (MedRa), causality, severity, predictability
452 and outcomes



453

454

455 Figure 1. Study flowchart: screening, enrollment, and vaccination.

456

457

458

459

Table 1. Demographic characteristics of all participants by study group.

VARIABLES	Adults 18 - 59 years old (n=487)		Elderly ≥60 years old (n=51)		TOTAL (N=538)	
	Age (years)					
Median (Q1 - Q3)	30.5	(25.5 - 41.6)	65.3	(64.2 - 68.9)	32	(26.0 - 46.0)
Sex, n (%)						
Female	276	(56.7)	31	(60.8)	307	(57.1)
Male	211	(43.3)	20	(39.2)	231	(42.9)
Ethnicity, n (%)						
White	389	(79.9)	30	(58.8)	419	(77.3)
Black	50	(10.3)	8	(15.7)	58	(10.8)
Multiracial	125	(25.7)	7	(13.7)	132	(24.5)
Indigenous	1	(0.2)	3	(5.9)	4	(0.7)
Asian	11	(2.3)	3	(5.9)	14	(2.6)
Other	11	(2.3)	0	(0.0)	11	(2.0)
Clinical Sites, n (%)						
Site 01	216	(44.4)	35	(68.6)	251	(46.7)
Site 02	180	(37.0)	16	(31.4)	196	(36.4)
Site 03	91	(18.7)	0	(0.0)	91	(16.9)

Q1: first quartile; Q3: third quartile

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.19.23294316>; this version posted August 23, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Table 2. Frequency of Adverse Events and Adverse Reactions after Coronavac vaccination (first and second dose) by study group.

STUDY GROUP	1st DOSE				2nd DOSE			
	AE n	Participants with AE n/n _{total} (%)	AE per participant		AE n	Participants with AE n/n _{total} (%)	AE per participant	
			median	(Q ₁ -Q ₃)			median	(Q ₁ -Q ₃)
Adults (18 - 59 years)	1569	392/487 (80.5)	3	(2 - 5)	554	218/438 (49.8)	2	(1 - 3)
Elderly (≥60 years)	136	30/51 (58.8)	3	(1 - 6)	94	28/50 (56.0)	3	(1 - 5)
TOTAL	1705	422/538 (78.4)	3	(2 - 5)	648	246/488 (50.4)	2	(1 - 3)
STUDY GROUP	1st DOSE				2nd DOSE			
	AR n	Participants with AR n/n _{total} (%)	AR per participant		AR n	Participants with AR n/n _{total} (%)	AR per participant	
			median	(Q ₁ -Q ₃)			median	(Q ₁ -Q ₃)
Adults (18 - 59 years)	1288	374/487 (76.8)	3	(1 - 5)	438	194/438 (44.3)	2	(1 - 3)
Elderly (≥60 years)	84	23/51 (45.1)	3	(1 - 4)	53	22/50 (44.0)	1	(1 - 4)
TOTAL	1372	397/538 (73.8)	3	(1 - 5)	491	216/488 (44.3)	2	(1 - 3)

Q1: first quartile; Q3: third quartile

AE: Adverse Event

AR: Adverse Reaction

Table 3. Frequency of solicited adverse reactions (AR) 7 days post vaccination in adults (18 - 59 years).

Solicited Adverse Reactions (AR)	1st DOSE			2nd DOSE		
	AR Adults (n=487)		AR Total	AR Adults (n=438)		AR Total
	n	%	n	n	%	n
Local						
Pain	256	52.6	263	129	29.5	132
Erythema	9	1.8	9	10	2.3	11
Swelling	15	3.1	15	3	0.7	4
Induration	10	2.1	11	3	0.7	3
Pruritus	15	3.1	15	4	0.9	4
Tenderness	166	34.1	169	59	13.5	59
Systemic						
Decreased appetite	20	4.1	20	6	1.4	7
Arthralgia	40	8.2	44	11	2.5	11
Chills	35	7.2	37	9	2.1	9
Headache	168	34.5	191	51	11.6	54
Diarrhea	36	7.4	38	14	3.2	15
Rash	8	1.6	8	1	0.2	1
Fatigue	107	22.0	127	23	5.3	25
Fever (Pyrexia)	14	2.9	14	5	1.1	5
Hypersensitivity (Allergic Reaction)	2	0.4	2	0	0.0	0
Myalgia	69	14.2	72	21	4.8	22
Nausea	39	8.0	43	16	3.7	17
Pruritus Outside the Administration Site	32	6.6	33	5	1.1	5
Cough	38	7.8	39	5	1.1	5
Vomiting	6	1.2	7	2	0.5	2
TOTAL SOLICITED	370	76.0	1157	186	42.5	391

Table 4. Frequency of solicited adverse reactions (AR) 7 days post vaccination in elderly (≥ 60 years).

Solicited Adverse Reactions (AR)	1st DOSE			2nd DOSE		
	AR Elderly (n=51)		AR Total	AR Elderly (n=50)		AR Total
	n	%	n	n	%	n
Local						
Pain	9	17.6	10	11	22.0	11
Swelling	0	0.0	0	1	2.0	1
Itching	1	2.0	1	2	4.0	2
Tenderness	8	15.7	8	1	2.0	1
Systemic						
Decreased Appetite	1	2.0	1	0	0.0	0
Arthralgia	7	13.7	9	4	8.0	4
Chills	3	5.9	4	4	8.0	6
Headache	9	17.6	9	10	20.0	12
Diarrhea	3	5.9	3	2	4.0	2
Rash	1	2.0	1	2	4.0	2
Fatigue	7	13.7	7	1	2.0	1
Fever (Pyrexia)	0	0.0	0	1	2.0	1
Myalgia	8	15.7	8	3	6.0	3
Nausea	2	3.9	2	2	4.0	2
Pruritus Outside the Administration Site	4	7.8	4	1	2.0	1
Cough	1	2.0	1	1	2.0	1
Vomiting	1	2.0	1	0	0.0	0
TOTAL SOLICITED	22	43.1	69	22	44.0	50

Table 5. Frequency of Adverse Reactions (AR) within 30 minutes post vaccination in adults (18 - 59 years) and elderly (≥ 60 years).

Solicited Adverse Reactions (AR)	1st DOSE			2nd DOSE			1st DOSE			2nd DOSE		
	AR Adults (n=487)		AR Total	AR Adults (n=438)		AR Total	AR Elderly (n=51)		AR Total	AR Elderly (n=50)		AR Total
	n	%	n	n	%	n	n	%	n	n	%	n
Local												
Pain	85	17.5	85	52	11.9	52	4	7.8	4	6	12.0	6
Erythema	2	0.4	2	2	0.5	2	0	0.0	0	0	0.0	0
Induration	5	1.0	5	3	0.7	3	0	0.0	0	0	0.0	0
Itching	1	0.2	1	1	0.2	1	0	0.0	0	1	2.0	1
Tenderness	48	9.9	48	32	7.3	32	2	3.9	2	1	2.0	1
Systemic												
Arthralgia	0	0.0	0	1	0.2	1	0	0.0	0	1	2.0	1
Headache	9	1.8	9	4	0.9	4	1	2.0	1	0	0.0	0
Fatigue	3	0.6	3	3	0.7	3	0	0.0	0	0	0.0	0
Myalgia	3	0.6	3	1	0.2	1	0	0.0	0	0	0.0	0
Nausea	3	0.6	3	2	0.5	2	0	0.0	0	0	0.0	0
Cough	1	0.2	1	1	0.2	1	0	0.0	0	0	0.0	0
Vomiting	0	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0
TOTAL SOLICITED	129	26.5	160	84	19.2	102	6	11.8	7	6	12.0	9